X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Chrysalin (rusalatide acetate) is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response, which is investigated for Acute Respiratory Distress Syndrome.
Lead Product(s): Rusalatide Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Chrysalin
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Chrysalis will conduct safety studies and additional options required to achieve Emergency Use Authorization and Animal Rule approval for TP508 as a medicinal treatment for acute and delayed effects of ionizing radiation exposure.
Lead Product(s): Rusalatide Acetate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TP508
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: BARDA
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Funding December 01, 2020
Details:
Funding from the NIAID COVID-19 contract is being used to complete in vivo testing of TP508 efficacy, drug product manufacture, and regulatory steps to initiate clinical trials in COVID-19 patients.
Lead Product(s): Rusalatide Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: TP508
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding August 11, 2020
Details:
This award will allow Chrysalis BioTherapeutics to evaluate TP508 as a potential solution to prevent thrombosis and systemic vascular damage caused by SARS-CoV-2 infection.
Lead Product(s): Rusalatide Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institute of Health
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Funding June 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
